Pharmaceutical company Janssen Pharmaceutical Companies reported on Tuesday the receipt of US Food and Drug Administration (FDA) Breakthrough Therapy Designation for its investigational prophylactic vaccine for the prevention of respiratory syncytial virus (RSV)-mediated lower respiratory tract disease in adults.
The company added that the investigational prophylactic vaccine is currently in a Phase 2b proof of concept study to investigate the safety and efficacy of the vaccine against RSV in adults aged 65 years and older.
Older adults aged 60 years or older are among the populations at highest risk of developing RSV, a highly-contagious, potentially life-threatening respiratory infection. RSV is a leading cause of bronchitis and pneumonia, affecting more than 64m people each year worldwide.
This US FDA breakthrough therapy designation was based on clinical data from the company's prophylactic RSV senior vaccine that may demonstrate substantial improvement compared to available standard of care on a clinically significant endpoint(s).2
Following the US FDA Breakthrough Therapy Designation, the company's prophylactic RSV senior vaccine candidate is now eligible for all associated FDA features.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma